PBH Stock Analysis: Prestige Brand Holdings | NYSE

Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 2.189m USD | 12M Return: -14.5% | US74112D1019 | Charts, Fundamentals & Technical Analysis

Analgesics, Digestive Health, Feminine Care, Oral Care
Total Rating 37
Safety 60
Buy Signal -1.02
Pharmaceuticals
Sub-Industry Rotation: +9.1
Market Cap: 2.19B
Avg Turnover: 28.2M
Risk 3d forecast
Volatility29.3%
VaR 5th Pctl4.78%
VaR vs Median-1.15%
Reward TTM
Sharpe Ratio-0.34
Rel. Str. IBD28.1
Rel. Str. Peer Group29.2 pctl
Character TTM
Beta-0.029
Beta Downside-0.026
Hurst Exponent0.423
Choppyness63.8%
Drawdowns 3y
Max DD51.76%
CAGR/Max DD-0.10
CAGR/Mean DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of PBH over the last years for every Quarter: "2021-09": 1.02, "2021-12": 0.99, "2022-03": 0.91, "2022-06": 1.09, "2022-09": 1.02, "2022-12": 1.04, "2023-03": 1.07, "2023-06": 1.06, "2023-09": 1.07, "2023-12": 1.06, "2024-03": 1.02, "2024-06": 0.9, "2024-09": 1.09, "2024-12": 1.22, "2025-03": 1.32, "2025-06": 0.95, "2025-09": 0.86, "2025-12": 1.14, "2026-03": 1.23, "2026-06": 0.98, "2026-09": 1.13,
EPS CAGR: 1.56%
EPS Trend: 35.6%
Last SUE: 0.82
Qual. Beats: 0
Revenue Revenue of PBH over the last years for every Quarter: 2021-09: 276.225, 2021-12: 274.47, 2022-03: 266.936, 2022-06: 277.059, 2022-09: 289.273, 2022-12: 275.524, 2023-03: 285.869, 2023-06: 279.309, 2023-09: 286.316, 2023-12: 282.741, 2024-03: 276.991, 2024-06: 267.142, 2024-09: 283.548, 2024-12: 290.317, 2025-03: 296.755, 2025-06: 249.53, 2025-09: 274.114, 2025-12: 283.444, 2026-03: 281.617, 2026-06: 265.71, 2026-09: 336.307,
Rev. CAGR: -0.10%
Rev. Trend: -5.1%
Last SUE: 0.67
Qual. Beats: 0

Warnings

Extended 1w
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan -1.1% 21
Feb +4.3% 14
Mar +1.2% 14
Apr -3.7% 14
May -2.1% 4
Jun +2.3% 14
Jul -0.0% 0
Aug -4.2% 14
Sep -4.1% 47
Oct +0.8% 4
Nov +4.2% 21
Dec +1.0% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: PBH Prestige Brand Holdings

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a US-based mid-cap healthcare company that develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products across North America, Australia, and other international markets. The company operates in two reporting segments: North American OTC Healthcare and International OTC Healthcare, reflecting its geographic diversification in the consumer health space. The OTC consumer healthcare sector is generally characterized by stable, recession-resistant demand driven by brand loyalty and repeat purchases of non-prescription remedies.

The company markets a broad portfolio of well-known OTC brands across categories including analgesics (BC, Goodys), baby care (Boudreauxs Butt Paste), oral care (Chloraseptic, DenTek, Ludens), eye care (Clear Eyes, TheraTears), womens health (Monistat, Summers Eve), digestive health (Gaviscon, Fleet), and other remedies such as Compound W, Debrox, Dramamine, Nix, Fess, and Hydralyte. This brand-heavy model is typical of the OTC pharmaceuticals sub-industry, where value is driven by consumer recognition and shelf placement rather than patented drug innovation.

Prestige sells its products through mass merchandisers, drug stores, food retailers, dollar stores, convenience stores, club stores, and e-commerce channels, leveraging a diversified distribution network that supports widespread product availability. Founded in 1996 and headquartered in Tarrytown, New York, the company was originally known as Prestige Brands Holdings, Inc. before rebranding to Prestige Consumer Healthcare Inc. in August 2018 to better reflect its focus on consumer health products.

Headlines to Watch Out For
  • North American OTC segment drives core revenue growth
  • Acquisition strategy expands brand portfolio with added leverage
  • Private label competition pressures pricing and margins
Piotroski VR-10 (Strict) 5.0
Net Income: 155.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.88 > 1.0
NWC/Revenue: 27.73% < 20% (prev 32.66%; Δ -4.93% < -1%)
CFO/TA 0.05 > 3% & CFO 229.8m > Net Income 155.1m
Net Debt (2.12b) to EBITDA (315.3m): 6.73 < 3
Current Ratio: 2.92 > 1.5 & < 3
Outstanding Shares: last quarter (47.6m) vs 12m ago -3.39% < -2%
Gross Margin: 52.01% > 18% (prev 56.36%; Δ -4.35% > 0.5%)
Asset Turnover: 28.59% > 50% (prev 32.27%; Δ -3.68% > 0%)
Interest Coverage Ratio: 4.22 > 6 (EBIT TTM 278.6m / Interest Expense TTM 66.1m)
Altman Z'' 2.89
A: 0.07 (Total Current Assets 492.1m - Total Current Liabilities 168.5m) / Total Assets 4.72b
B: 0.38 (Retained Earnings 1.80b / Total Assets 4.72b)
C: 0.07 (EBIT TTM 278.6m / Avg Total Assets 4.08b)
D: 0.70 (Book Value of Equity 1.94b / Total Liabilities 2.78b)
Altman-Z'' = 2.89 = A
Beneish M -2.75
DSRI: 1.17 (Receivables 244.1m/199.0m, Revenue 1.17b/1.11b)
GMI: 1.08 (GM 56.36% / 52.01%)
AQI: 1.05 (AQ_t 0.86 / AQ_t-1 0.82)
SGI: 1.05 (Revenue 1.17b / 1.11b)
TATA: -0.02 (NI 155.1m - CFO 229.8m) / TA 4.72b)
Beneish M = -2.75 (Cap -4..+1) = A
What is the price of PBH shares?

As of November 20, 2026, the stock is trading at USD 49.60 with a total of 510,790 shares traded. Over the past week, the price has changed by +14.60%, over one month by +1.83%, over three months by +0.10% and over the past year by -14.46%.

Current recommended Stop Loss: 45.60 (which is 8.1% or 1.9 ATR below the current price).

Is PBH a buy, sell or hold?

Prestige Brand Holdings has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PBH.

  • StrongBuy: 5
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PBH price?
Analysts Target Price 66.2 33.5%
Prestige Brand Holdings (PBH) - Fundamental Data Overview as of 15 November 2026
Market Cap USD = 2.19b (2.19b USD * 1.0 USD.USD)
P/E Trailing = 14.2562
P/E Forward = 10.0908
P/S = 1.8759
P/B = 1.1046
P/EG = 1.2858
Revenue TTM = 1.17b USD
EBIT TTM = 278.6m USD
EBITDA TTM = 315.3m USD
Long Term Debt = 2.08b USD (from longTermDebt, last quarter)
Short Term Debt = 9.96m USD (from shortTermDebt, last quarter)
Debt = 2.17b USD (from shortLongTermDebtTotal, last quarter) + Leases 44.0m
Net Debt = 2.12b USD (calculated: Debt 2.17b - CCE 46.5m)
Enterprise Value = 4.31b USD (2.19b + Debt 2.17b - CCE 46.5m)
Interest Coverage Ratio = 4.22 (Ebit TTM 278.6m / Interest Expense TTM 66.1m)
EV/FCF = 20.12x (Enterprise Value 4.31b / FCF TTM 214.2m)
FCF Yield = 4.97% (FCF TTM 214.2m / Enterprise Value 4.31b)
FCF Margin = 18.35% (FCF TTM 214.2m / Revenue TTM 1.17b)
Net Margin = 13.29% (Net Income TTM 155.1m / Revenue TTM 1.17b)
Gross Margin = 52.01% ((Revenue TTM 1.17b - Cost of Revenue TTM 560.1m) / Revenue TTM)
Gross Margin QoQ = 51.30% (prev 51.25%)
Tobins Q-Ratio = 0.91 (Enterprise Value 4.31b / Total Assets 4.72b)
Interest Expense / Debt = 3.05% (Interest Expense 66.1m / Debt 2.17b)
Taxrate = 27.04% (57.5m / 212.6m)
NOPAT = 203.3m (EBIT 278.6m * (1 - 27.04%))
Current Ratio = 2.92 (Total Current Assets 492.1m / Total Current Liabilities 168.5m)
Debt / Equity = 1.11 (Debt 2.17b / totalStockholderEquity, last quarter 1.94b)
Debt / EBITDA = 6.73 (Net Debt 2.12b / EBITDA 315.3m)
Debt / FCF = 9.90 (Net Debt 2.12b / FCF TTM 214.2m)
Total Stockholder Equity = 1.89b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.80% (Net Income 155.1m / Total Assets 4.72b)
RoE = 8.19% (Net Income TTM 155.1m / Total Stockholder Equity 1.89b)
RoCE = 7.01% (EBIT 278.6m / Capital Employed (Equity 1.89b + L.T.Debt 2.08b))
RoIC = 4.50% (NOPAT 203.3m / Invested Capital 4.52b)
WACC = 3.89% (E(2.19b)/V(4.36b) * Re(5.54%) + D(2.17b)/V(4.36b) * Rd(3.05%) * (1-Tc(0.27)))
Discount Rate = 5.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.65 | Cagr: -2.40%
[DCF] Terminal Value 73.10% ; FCFF base≈230.7m ; Y1≈202.3m ; Y5≈163.5m
[DCF] Fair Price = 10.61 (EV 2.62b - Net Debt 2.12b = Equity 502.9m / Shares 47.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 35.58 | EPS CAGR: 1.56% | SUE: 0.82 | # QB: 0
Revenue Correlation: -5.07 | Revenue CAGR: -0.10% | SUE: 0.67 | # QB: 0
EPS current Quarter (2026-12-31): EPS=1.05 | Chg30d=-15.28% | Revisions=-57% | Analysts=6
EPS current Year (2027-03-31): EPS=4.50 | Chg30d=-1.54% | Revisions=-38% | GrowthEPS=+2.7% | GrowthRev=+17.8%
EPS next Year (2028-03-31): EPS=5.08 | Chg30d=+0.07% | Revisions=+0% | GrowthEPS=+13.1% | GrowthRev=+6.9%
[Analyst] Revisions Ratio: -44% (up=3, down=10)